Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Reportable Segments

The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands):

	Three Months Ended September 30, 2022
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other			Consolidated
Revenue	$	8,502	$	5,111	$	—		$	13,613
Other revenue		—		—		1			1
Interest expense		82		—		—			82
Manufacturing, research and development		—		1,792		—			1,792
Depreciation and amortization expense		—		632		2			634
General and administrative		115		843		3,391			4,349
Other income, net		1,801		—		—			1,801
Income tax expense		—		—		1,942			1,942
Net income (loss)		10,106		1,844		(5,334	)		6,616

	Three Months Ended September 30, 2021
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	9,373	$	187		$	—		$	9,560
Interest expense		53		—			—			53
Manufacturing, research and development		—		2,487			—			2,487
Depreciation and amortization expense		—		810			2			812
General and administrative		90		999			2,491			3,580
Other income, net		128		—			—			128
Income tax expense		—		—			513			513
Net income (loss)		9,358		(4,109	)		(3,006	)		2,243

	Nine Months Ended September 30, 2022
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	25,745	$	5,461		$	—		$	31,206
Other revenue		—		480			1			481
Interest expense		242		—			—			242
Manufacturing, research and development		—		5,173			—			5,173
Depreciation and amortization expense		—		1,961			3			1,964
General and administrative		219		2,783			7,525			10,527
Other income, net		89		—			—			89
Income tax expense		—		—			3,211			3,211
Net income (loss)		25,373		(3,976	)		(10,738	)		10,659

	Nine Months Ended September 30, 2021
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	29,857	$	10,846		$	—		$	40,703
Other revenue		—		496			—			496
Interest expense		292		—			—			292
Manufacturing, research and development		—		5,577			—			5,577
Depreciation and amortization expense		—		3,300			5			3,305
Change in fair value of acquisition-related contingent consideration		—		(147	)		—			(147	)
General and administrative		2,034		3,088			4,703			9,825
Other income, net		2,235		—			—			2,235
Income tax expense		—		—			4,980			4,980
Net income (loss)		29,766		(476	)		(9,688	)		19,602

[custom:DisclosureSegmentInformationDetailsAbstract]

	Three Months Ended September 30, 2022
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other			Consolidated
Revenue	$	8,502	$	5,111	$	—		$	13,613
Other revenue		—		—		1			1
Interest expense		82		—		—			82
Manufacturing, research and development		—		1,792		—			1,792
Depreciation and amortization expense		—		632		2			634
General and administrative		115		843		3,391			4,349
Other income, net		1,801		—		—			1,801
Income tax expense		—		—		1,942			1,942
Net income (loss)		10,106		1,844		(5,334	)		6,616

	Three Months Ended September 30, 2021
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	9,373	$	187		$	—		$	9,560
Interest expense		53		—			—			53
Manufacturing, research and development		—		2,487			—			2,487
Depreciation and amortization expense		—		810			2			812
General and administrative		90		999			2,491			3,580
Other income, net		128		—			—			128
Income tax expense		—		—			513			513
Net income (loss)		9,358		(4,109	)		(3,006	)		2,243

	Nine Months Ended September 30, 2022
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	25,745	$	5,461		$	—		$	31,206
Other revenue		—		480			1			481
Interest expense		242		—			—			242
Manufacturing, research and development		—		5,173			—			5,173
Depreciation and amortization expense		—		1,961			3			1,964
General and administrative		219		2,783			7,525			10,527
Other income, net		89		—			—			89
Income tax expense		—		—			3,211			3,211
Net income (loss)		25,373		(3,976	)		(10,738	)		10,659

	Nine Months Ended September 30, 2021
	Finance Receivables		Pharmaceutical Development and Other			Holding Company and Other			Consolidated
Revenue	$	29,857	$	10,846		$	—		$	40,703
Other revenue		—		496			—			496
Interest expense		292		—			—			292
Manufacturing, research and development		—		5,577			—			5,577
Depreciation and amortization expense		—		3,300			5			3,305
Change in fair value of acquisition-related contingent consideration		—		(147	)		—			(147	)
General and administrative		2,034		3,088			4,703			9,825
Other income, net		2,235		—			—			2,235
Income tax expense		—		—			4,980			4,980
Net income (loss)		29,766		(476	)		(9,688	)		19,602